ATLAS GROWERS LTD. (“Atlas” or the “Company”), a wholly owned subsidiary of Atlas Biotechnologies Inc., announces the submission of its Affirmation of Readiness and Video Evidence Package (“Evidence Package”) to Health Canada. The submission of the Evidence Package is the final step related to the receipt of a cultivation license from Health Canada under the Access to Cannabis for Medical Purposes Regulations (ACMPR). The submission of the Evidence Package is a significant achievement for Atlas in its preparation to become a leading provider of medicinal cannabis.

President and Chief Executive Officer Sheldon Croome states; “We are extremely pleased to have submitted the required documentation to Health Canada to produce medicinal cannabis. With the completion of our state-of-the-art medicinal cannabis facility, development permits for up to 1,000,000 square feet of cultivation expansion (which utilizing proprietary technologies could be configured into 2,000,000 square feet of growing capacity) and recent additions to our Advisory Board with related experience in research and development, regulation and import and export, Atlas is well positioned to be a global leader in the cannabis industry.”


Health Canada inspections are conducted to assess and monitor compliance with the ACMPR, Controlled Drugs and Substances Act (CDSA) regulation and the Food and Drugs Act (FDA), as they apply to cannabis for medical purposes. It is anticipated that new cultivation licenses for the industry will be granted after October 17, 2018, the specified date for legalization of cannabis in Canada.

About Atlas Growers Ltd.

Atlas is based in Edmonton, Alberta, Canada and is a wholly owned subsidiary of Atlas Biotechnologies Inc. Atlas expects to receive its sales license by the end of 2018. Atlas’ initial purpose-built 38,000 square foot facility is in the final stages of equipping the growing rooms and labs and will have the capacity to produce approximately 5,000 kg of dried cannabis annually as well as to refine cannabis concentrates. Further, the 160-acre Atlas site could allow for significant future expansion of Atlas’ cultivation capacity. Atlas is well financed and has a currently unutilized $6.25 million bank facility in place with ATB Financial.

For further information contact:

Jeffrey R. Gossain, P. Eng.
Vice President of Operations
Phone: 780-784-5920
Email: jeff@atlasgrowers.com
Website: www.atlasgrowers.com

Graeme Dick, BMgmt
Colwell Capital Corp.
403-561-8989
graeme@colwellcapital.com

Dean Stuart
403-617-7609
dean@boardmarker.net

Source: globenewswire.com

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less